Clinical Trial Update: A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

View source ↗

Summary

A completed observational study in the United States evaluating icatibant for treating attacks in patients with hereditary angioedema types I and II.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ICATIBANT (icatibant)

Snippet

Sponsor: KalVista Pharmaceuticals, Ltd. | Conditions: Hereditary Angioedema | Status: COMPLETED